Patents Represented by Attorney Joseph J. Borovian
  • Patent number: 7012085
    Abstract: The invention provides compounds of formula (I) wherein R0, R1, R2 and A are as defined in the description, and the preparation thereof. The compounds of formula (I) have high affinity as ?2 adrenoceptors and hence are useful as pharmaceuticals.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: March 14, 2006
    Assignee: Novartis AG
    Inventors: Max Peter Seiler, Joachim Nozulak
  • Patent number: 6958331
    Abstract: The invention relates to sulfonyl amine derivatives of formula IA wherein R5A, X1, X2, R9 and R10 are as defined herein, which derivatives are useful as bradykinin B1 receptor antagonists.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: October 25, 2005
    Assignee: Novartis AG
    Inventors: Christopher Thomas Brain, William Cantrell, Andrew James Culshaw, Edward Karol Dziadulewicz, Terance William Hart, Timothy John Ritchie, Liladhar Waykole
  • Patent number: 6833367
    Abstract: The present invention relates to certain substituted polyketides of formula I, wherein A, B and C are as defined herein, pharmaceutical compositions containing said compounds, and the use of said compounds in treating tumors.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: December 21, 2004
    Assignee: Novartis AC
    Inventors: Frederick R. Kinder, Jr., Kenneth W. Bair, Timothy M. Ramsey, Michael L. Sabio
  • Patent number: 6790861
    Abstract: The invention relates to the use of certain acid donors as stabilizers in pharmaceutical compositions, and to the stabilized pharmaceutical compositions resulting therefrom.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: September 14, 2004
    Assignee: Novartis AG
    Inventors: Richard V. Vivilecchia, Bruce A. Ross
  • Patent number: 6780861
    Abstract: The invention provides compounds of formula (I) wherein n, A, R1, R2 and R3 are as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as pharmaceuticals.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: August 24, 2004
    Assignee: Novartis AG
    Inventor: Joachim Nozulak
  • Patent number: 6756367
    Abstract: The invention provides a compound of formula I wherein X, R1, R2 and Het are as defined in the description, and a process for preparing them. The compounds of formula I are useful as pharmaceuticals.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: June 29, 2004
    Assignee: Novartis AG
    Inventor: Bernhard Peter Neumann
  • Patent number: 6740669
    Abstract: The invention relates to the novel modification A or A′ of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula its use and pharmaceutical preparations comprising this crystal modification.
    Type: Grant
    Filed: September 8, 1998
    Date of Patent: May 25, 2004
    Assignee: Novartis AG
    Inventors: Robert Portmann, Urs Christoph Hofmeier, Andreas Burkhard, Walter Scherrer, Martin Szelagiewicz
  • Patent number: 6734177
    Abstract: The present invention relates to certain salts of discodermolide acid, pharmaceutical compositions containing said salts, the use of said salts in treating tumors and to a process for making said salts.
    Type: Grant
    Filed: April 15, 2002
    Date of Patent: May 11, 2004
    Assignee: Novartis AG
    Inventors: Frederick R. Kinder, Jr., Prasad K. Kapa, Eric M. Loeser
  • Patent number: 6723742
    Abstract: The use is described of 3,5-diphenyl-1,2,4-triazoles of the formula I in which R1-R5 are as defined in the description. The compounds have useful pharmaceutical properties and are particularly active as iron chelators. They can be used for the treatment of iron overload in warm-blooded animals.
    Type: Grant
    Filed: May 29, 2003
    Date of Patent: April 20, 2004
    Assignee: Novartis AG.
    Inventors: René Lattmann, Pierre Acklin
  • Patent number: 6710047
    Abstract: The invention relates to compounds of formula I, wherein r is 0 to 2, n is 0 to 2; m is 0 to 4; R1 and R2 (i) are in each case a lower alkyl, or (ii) together form a bridge in subformula I* or (iii) together form a bridge in subformula I** wherein one or two of the ring members T1, T2, T3, and T4 are nitrogen, and the remainder are in each case CH; A, B, D, and E are N or CH, wherein not more than 2 of these radicals are N; G is lower alkylene, acyloxy- or hydroxy-lower alkylene, —CH2—O—, —CH2—S—, —CH2—NH—, oxa, thia, or imino; Q is methyl; R is H or lower alkyl; X is imino, oxa, or thia; Y is aryl, pyridyl, or (un)substituted cycloalkyl; and Z is mono- or disubstited amino, halogen, alkyl, substituted alkyl, hydroxy, etheritied or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, p
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: March 23, 2004
    Assignee: Novartis AG
    Inventors: Guido Bold, Jörg Frei, Peter Traxler, Karl-Heinz Altmann, Helmut Mett, David Raymond Stover, Jeanette Marjorie Wood
  • Patent number: 6677328
    Abstract: Method for the prevention of colonic adenomas in mammals at risk of developing them by administering to such mammals an effective colonic adenoma preventive amount of ursodiol or a pharmaceutically acceptable salt conjugation product thereof.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: January 13, 2004
    Assignees: Novartis Corp., University of Chicago, University of Arizona
    Inventors: Carroll Wayne Allen, Thomas Albert Brasitus, David Lewis Earnest, Gerald Leigh Messerschmidt
  • Patent number: 6656957
    Abstract: A compound of formula I wherein X represents an optionally halo-substituted (C2-4)alkynylene group bonded via vicinal unsaturated carbon atoms.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: December 2, 2003
    Assignees: Novartis AG, Sibia Neurosciences Inc.
    Inventors: Hans Allgeier, Yves Auberson, Michel Biollaz, Nicholas David Cosford, Fabrizio Gasparini, Roland Heckendorn, Edwin Carl Johnson, Rainer Kuhn, Mark Andrew Varney, Gönül Veliçelebi
  • Patent number: 6635647
    Abstract: The invention provides compounds of formula (I) wherein A, B and R are as defined herein and the preparation thereof. The compounds of formula (I) are useful as somatostatin antagonists.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: October 21, 2003
    Assignee: Novartis AG
    Inventor: Thomas J. Troxler
  • Patent number: 6617340
    Abstract: The invention discloses certain N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing said compounds as an active ingredient thereof, and the use of said compounds in inhibiting dipeptidyl peptidase-IV.
    Type: Grant
    Filed: July 19, 2000
    Date of Patent: September 9, 2003
    Assignee: Novartis AG
    Inventor: Edwin Bernard Villhauer
  • Patent number: 6608071
    Abstract: The invention relates to compounds of formula I wherein r is from 0 to 2; n is from 0 to 2; m is from 0 to 4; A, B, D and E are each independently of the others N or CH, with the proviso that not more than two of those radicals are N; G is lower alkylene, —CH2—O—, —CH2—S—, —CH2—NH—, oxa (—O—), thia (—S—) or imino (—NH—), or is lower alkylene substituted by acyloxy or by hydroxy; Q is lower alkyl, especially methyl; R is H or lower alkyl; X is imino, oxa or thia; Y is lower alkyl or, especially, aryl, heteroaryl or unsubstituted or substituted cycloalkyl; and Z is amino, mono- or di-substituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower alkylthio, alkylphenylthio, phenylsulfinyl, phenyl-lowe
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: August 19, 2003
    Assignee: Novartis AG
    Inventors: Karl-Heinz Altmann, Guido Bold, Paul William Manley
  • Patent number: 6599898
    Abstract: The present invention relates to certain substituted caprolactam carbonate and ether compounds, pharmaceutical compositions containing said compounds, the use of said compounds in treating tumors and to a process for making said compounds.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: July 29, 2003
    Assignee: Novartis AG
    Inventors: Frederick Ray Kinder, Jr., Richard William Versace, Kenneth Walter Bair
  • Patent number: 6596750
    Abstract: The use is described of 3,5-diphenyl-1,2,4-triazoles of the formula I in which R1-R5 are as defined in the description. The compounds have useful pharmaceutical properties and are particularly active as iron chelators. They can be used for the treatment of iron overload in warm-blooded animals.
    Type: Grant
    Filed: September 23, 2002
    Date of Patent: July 22, 2003
    Assignee: Novartis AG
    Inventors: René Lattmann, Pierre Acklin
  • Patent number: 6565883
    Abstract: Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: May 20, 2003
    Assignee: Novartis AG
    Inventors: Jörg Ogorka, Oskar Kalb, Rajen Shah, Satish Chandra Khanna
  • Patent number: 6555533
    Abstract: The present invention relates to certain substituted caprolactam compounds, pharmaceutical compositions containing said compounds, the use of said compounds in treating tumors and to a process for making said compounds.
    Type: Grant
    Filed: March 12, 2001
    Date of Patent: April 29, 2003
    Assignee: Novartis AG
    Inventors: Frederick Ray Kinder, Jr., Kenneth Walter Bair, Christopher Turchik Jagoe, Richard William Versace, Sompong Wattanasin
  • Patent number: 6545148
    Abstract: The present invention relates to an improved process for preparing certain substituted caprolactam compounds which comprises acylating an aminocaprolactam compound with a lactone compound in the presence of a weak base and a polar, organic solvent, and hydrolyzing the resultant diamide compound in a mixture of solvents to obtain the desired caprolactam compound.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: April 8, 2003
    Assignee: Novartis AG
    Inventors: David Daqiang Xu, Wenming Liu